Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Operational Highlights
MRK logo

Merck's Q3 Sales Rise 4% on Oncology Strength, Verona Acquisition Bolsters Respiratory

MRK10-QFiling Date: 11/6/2025
Merck & Co., Inc.
Description

What this story covers

Merck's Q3 2025 sales hit $17.3B, up 4% YoY, driven by oncology; non-GAAP EPS $2.58. Key Verona Pharma buy expands COPD pipeline. Strong liquidity $18.2B funds R&D, dividends. Legal risks managed; patents protect key drugs amid biosimilar threats.

Story snapshot

CompanyMerck & Co., Inc.
TickerMRK
VariantStandard detailed
Duration15:18
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000310158-25-000059

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in